Business
CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy
FILSPARI® (sparsentan) suggested for IgA Nephropathy patients who are at risk of progressive kidney function loss SAN DIEGO & ST. GALLEN,
About this update from Travere Therapeutics, Inc.
[{"type":"text","content":"\nFILSPARI® (sparsentan) suggested for IgA Nephropathy patients who are at risk of progressive kidney function loss\n\n\n SAN DIEGO & ST. GALLEN, Switzerland--(BUSINESS WIRE)--\nCSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) support the recent publication of the updated clinical practice guidelines for the treatment of IgA Nephropathy (IgAN), Kidney Disease: Improving Global Outcomes (KDIGO) 2025 clinical practice guideline for the management of IgA Nephropathy and Immunoglobulin A vasculitis. The updated guidelines define diagnostic criteria, treatment goals and treatment approaches, aiming for progress for people living with IgAN and the clinicians who treat them.\n\n\nThe 2025 update defines remission of proteinuria (","length":1013,"tagName":"div"}]